The UK’s Innovative Licensing and Access Pathway (ILAP) was relaunched in 2025 and introduces a more selective, better defined and operationally coordinated framework for supporting transformative therapies, including many advanced therapies.
Drawing on practical experience from the CGT Catapult’s involvement with the scheme through the CERSI-AT programme, this white paper highlights key recommendations for developers entering the relaunched ILAP, such as:
- Prepare a robust, evidence based Innovation Passport application
- Begin Target Development Profile (TDP) development early
- Use the TDP meeting strategically
- Align clinical and commercial evidence generation plans early
By combining ILAP’s structured engagement with early, strategic evidence planning, developers can reduce uncertainty, strengthen their value proposition and improve the likelihood of timely, successful adoption of transformative therapies within the UK healthcare system.
